Striatal glutamate and the conversion to psychosis: A prospective 1H-MRS imaging study

International Journal of Neuropsychopharmacology

Volumn 16, Issue 2, 2013, Pages 471-475

  De La Fuente Sandoval, Camilo ^a   León Ortiz, Pablo ^a   Azcárraga, Mariana ^a   Favila, Rafael ^b   Stephano, Sylvana ^a   Graff Guerrero, Ariel ^c  

^a NATIONAL INSTITUTE OF NEUROLOGY AND NEUROSURGERY   (Mexico)

^b GE HEALTHCARE   (United Kingdom)

^c UNIVERSITY OF TORONTO   (Canada)

Author keywords

1H MRS; Associative striatum; glutamate; prodromal; psychosis

Indexed keywords

GLUTAMIC ACID;

ADULT; ARTICLE; BRAIN LEVEL; CLINICAL ARTICLE; CONTROLLED STUDY; CORPUS STRIATUM; DISEASE COURSE; EDUCATIONAL STATUS; EFFECT SIZE; FEMALE; FOLLOW UP; HANDEDNESS; HUMAN; MALE; PRIORITY JOURNAL; PROTON NUCLEAR MAGNETIC RESONANCE; PSYCHOSIS; SCHIZOAFFECTIVE PSYCHOSIS; SCHIZOPHRENIA; SCHIZOPHRENIFORM DISORDER;

ADOLESCENT; CORPUS STRIATUM; FEMALE; GLUTAMIC ACID; HUMANS; MAGNETIC RESONANCE SPECTROSCOPY; MALE; PROSPECTIVE STUDIES; PROTONS; PSYCHIATRIC STATUS RATING SCALES; PSYCHOTIC DISORDERS; YOUNG ADULT;

EID: 84875956590     PISSN: 14611457     EISSN: 14695111     Source Type: Journal    
DOI: 10.1017/S1461145712000314     Document Type: Article

References (22)

1. Breier A, Adler CM, Weisenfeld N, Su TP, et al. (1998). Effects of NMDA antagonism on striatal dopamine release in healthy subjects: application of a novel PET approach. Synapse 29, 142-147.
2. Cannon TD, Cadenhead K, Cornblatt B, Woods SW, et al. (2008). Prediction of psychosis in youth at high clinical risk: a multisite longitudinal study in North America. Archives of General Psychiatry 65, 28-37.
3. Carlsson M, Carlsson A (1990). Interactions between glutamatergic and monoaminergic systems within the basal ganglia-implications for schizophrenia and Parkinson's disease. Trends in Neurosciences 13, 272-276.
4. de la Fuente-Sandoval C, Leon-Ortiz P, Favila R, Stephano S, et al. (2011). Higher levels of glutamate in the associative-striatum of subjects with prodromal symptoms of schizophrenia and patients with first-episode psychosis. Neuropsychopharmacology 36, 1781-1791.
5. First MB, Spitzer RL, Williams JB, Gibbon M (1997). Structured Clinical Interview for DSM-IV Disorders (SCID). Washington, DC: American Psychiatric Association.
6. Grace AA (2000). Gating of information flow within the limbic system and the pathophysiology of schizophrenia. Brain Research, Brain Research Reviews 31, 330-341.
7. Howes OD, Bose SK, Turkheimer F, Valli I, et al. (2011). Dopamine synthesis capacity before onset of psychosis: a prospective [18F]-DOPA PET imaging study. American Journal of Psychiatry 168, 1311-1317.
8. Howes OD, Kapur S (2009). The dopamine hypothesis of schizophrenia: version III-the final common pathway. Schizophrenia Bulletin 35, 549-562.
9. Javitt DC, Zukin SR (1991). Recent advances in the phencyclidine model of schizophrenia. American Journal of Psychiatry 148, 1301-1308.
10. Kegeles LS, Abi-Dargham A, Frankle WG, Gil R, et al. (2010). Increased synaptic dopamine function in associative regions of the striatum in schizophrenia. Archives of General Psychiatry 67, 231-239.
11. Kegeles LS, Abi-Dargham A, Zea-Ponce Y, Rodenhiser-Hill J, et al. (2000). Modulation of amphetamine-induced striatal dopamine release by ketamine in humans: implications for schizophrenia. Biological Psychiatry 48, 627-640.
12. Miller TJ, McGlashan TH, Rosen JL, Cadenhead K, et al. (2003). Prodromal assessment with the structured interview for prodromal syndromes and the scale of prodromal symptoms: predictive validity, interrater reliability, and training to reliability. Schizophrenia Bulletin 29, 703-715.
13. Moghaddam B, Javitt D (2012). From revolution to evolution: the glutamate hypothesis of schizophrenia and its implication for treatment. Neuropsychopharmacology 37, 4-15.
14. Olney JW, Farber NB (1995). Glutamate receptor dysfunction and schizophrenia. Archives of General Psychiatry 52, 998-1007.
15. Provencher SW (1993). Estimation of metabolite concentrations from localized in vivo proton NMR spectra. Magnetic Resonance in Medicine 30, 672-679.
16. Ruhrmann S, Schultze-Lutter F, Salokangas RK, Heinimaa M, et al. (2010). Prediction of psychosis in adolescents and young adults at high risk: results from the prospective European prediction of psychosis study. Archives of General Psychiatry 67, 241-251.
17. Stone JM, Day F, Tsagaraki H, Valli I, et al. (2009). Glutamate dysfunction in people with prodromal symptoms of psychosis: relationship to gray matter volume. Biological Psychiatry 66, 533-539.
18. Stone JM, Howes OD, Egerton A, Kambeitz J, et al. (2010). Altered relationship between hippocampal glutamate levels and striatal dopamine function in subjects at ultra high risk of psychosis. Biological Psychiatry 68, 599-602.
19. Wood SJ, Berger G, Velakoulis D, Phillips LJ, et al. (2003). Proton magnetic resonance spectroscopy in first episode psychosis and ultra high-risk individuals. Schizophrenia Bulletin 29, 831-843.
20. Yamamoto H, Kitamura N, Lin XH, Ikeuchi Y, et al. (1999). Differential changes in glutamatergic transmission via N-methyl-D-Aspartate receptors in the hippocampus and striatum of rats behaviourally sensitized to methamphetamine. International Journal of Neuropsychopharmacology 2, 155-163.
21. Yung AR, McGorry PD (1996). The prodromal phase of first-episode psychosis: past and current conceptualizations. Schizophrenia Bulletin 22, 353-370.
22. Yung AR, Phillips LJ, Yuen HP, Francey SM, et al. (2003). Psychosis prediction: 12-month follow up of a high-risk ('prodromal') group. Schizophrenia Research 60, 21-32.